Patient response, survival time, and tumor staining characteristics in biochemotherapy protocol
Patient characteristics | Immunohistochemistry | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient no. | Response | Survival time (mo)a | Status | iNOS | NT | ||||||||
First diagnosisb | First treatment dayc | Pretreatment | Posttreatment | ||||||||||
1 | Rd | 17 | 9 | DOD | ++ | +++ | − | ||||||
2 | NR | 20 | 14 | DOD | N/A | ++ | ++ | ||||||
3 | R | 33 | 32 | DOD | N/A | ++ | ++ | ||||||
4 | NR | 21 | 17 | DOD | − | + | − | ||||||
5 | NR | 59 | 18 | DOD | ++ | +++ | ++ | ||||||
6 | R | ? | 19 | DOD | N/A | ++ | ++ | ||||||
7 | NR | 40 | 22 | DOD | N/A | ++ | + | ||||||
8 | NR | 29 | 28 | DOD | N/A | + | − | ||||||
9 | NR | 26 | 25 | DOD | ++ | + | ++ | ||||||
10 | NR | 30 | 29 | DOD | ++ | +++ | +++ | ||||||
11 | NR | 67 | 44 | DOD | N/A | ++ | ++ | ||||||
12 | NR | ? | 48 | DOD | N/A | − | − | ||||||
15 | R | 54+ | 53+ | ANED | N/A | − | − | ||||||
16 | NR | 74+ | 56+ | AWD | − | − | − | ||||||
13 | NR | 72+ | 61+ | AWD | − | − | − | ||||||
14 | NR | 74+ | 61+ | ANED | N/A | − | − | ||||||
20 | R | 69+ | 60+ | ANED | − | − | − | ||||||
17 | R | 99+ | 65+ | ANED | N/A | − | − | ||||||
19 | NR | ? | 65+ | ANED | − | − | − | ||||||
18 | R | 92+ | 66+ | ANED | +++ | ++ | +++ |
a–c Survival measured from:
b the date of primary tumor diagnosis, and
c the initiation of treatment.
d R, major response; NR, absence of major response; DOD, dead of disease; ANED, alive with no evidence of disease; AWD, alive with disease; N/A, not available; ?, not known.